Encompass Health (EHC) Q2 2026 Earnings Call Transcript

Encompass Health reported Q2 net operating revenue of $1.597B (+9.6% y/y), with adjusted EBITDA of $348M (+9.2%) and adjusted EPS of $1.55 (+10.7%). Management raised 2026 guidance to $6.41B–$6.49B revenue, $1.365B–$1.395B adjusted EBITDA, and $6.02–$6.25 adjusted EPS, alongside a 2.3% CMS IRF rule-driven increase in Medicare net revenue per discharge effective Oct. 1, 2026. The company also boosted capital returns (additional ~$74.2M Q2 repurchases, quarterly dividend to $0.21/share, and $1B repurchase authorization) while maintaining net leverage of 1.9x. Sector read-through is supported by improved operating metrics (occupancy 77.4%, +290 bps y/y; premium labor costs down) and expansion momentum (139 beds added in 1H 2026 with further 250-bed openings planned for H2).

Analysis

This is still a capacity-and-mix story, not just a reimbursement story. The important mechanism is that incremental beds are being layered into an already tight network, so new volume should carry better marginal economics than the legacy base: higher occupancy improves EPOB, lower turnover reduces premium labor, and more medically complex cases lift revenue per discharge without requiring a commensurate step-up in fixed costs. That combination usually supports both estimate revisions and a multiple re-rate versus lower-growth healthcare services names.

The second-order winner is not only EHC itself but also its acute-care referral partners and JV sponsors, who gain a faster downstream discharge option and lower length-of-stay pressure. The loser is the Medicare Advantage pre-auth model: if the company can scale its appeals workflow, it effectively converts administrative friction into incremental admissions, which forces MA plans to choose between higher approval rates or higher processing costs. Over 1-3 months, the stock should trade on whether investors believe the admit-and-appeal pilot is a repeatable conversion engine rather than a one-off win.

The key risks are timing and sustainability. If MA denials re-accelerate, if wage inflation re-broadens above the low-single-digit range, or if acuity normalizes while occupancy plateaus, the earnings bridge will compress quickly because the current beat is partly a mix of operating leverage and non-recurring tax noise. The contrarian view is that the market may still be underestimating the structural runway from deregulation and small-format expansion: this is a multi-year supply constraint release, not just a quarterly utilization pop.

Key Decisions for Investors

• Long EHC on any post-earnings consolidation over the next 1-4 weeks; thesis is estimate revisions driven by occupancy and labor leverage, with a 6-18 month upside case if new beds ramp on schedule.
• Pair trade: long EHC / short a managed-care basket (UNH, HUM, ELV) for 1-3 months to express the view that MA pre-auth friction remains an operating tax on payers while EHC monetizes the same friction through higher admission capture.
• Use EHC call spreads rather than outright common if initiating after a pullback; the setup is a medium-duration rerating trade, but premium labor and denials are the main near-term falsifiers.
• Set a watch alert if same-store discharge growth drops back below low-single digits or SWB per FTE re-accelerates above ~4.5%; that would indicate the labor/acuity operating leverage is peaking.